S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.85 (-1.17%)
MSFT   329.98 (-0.03%)
FB   308.19 (-0.78%)
GOOGL   2,855.73 (+1.23%)
AMZN   3,434.48 (-0.27%)
TSLA   1,075.21 (-1.81%)
NVDA   321.28 (+2.20%)
BABA   120.58 (-1.56%)
NIO   35.14 (-8.27%)
CGC   9.91 (-0.30%)
AMD   149.73 (+0.42%)
GE   94.99 (+2.14%)
MU   82.82 (-2.74%)
T   23.13 (+4.05%)
F   19.80 (+1.12%)
DIS   146.18 (+2.84%)
PFE   53.47 (-2.21%)
AMC   29.70 (+3.96%)
ACB   5.93 (-1.33%)
BA   198.15 (+5.29%)
S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.85 (-1.17%)
MSFT   329.98 (-0.03%)
FB   308.19 (-0.78%)
GOOGL   2,855.73 (+1.23%)
AMZN   3,434.48 (-0.27%)
TSLA   1,075.21 (-1.81%)
NVDA   321.28 (+2.20%)
BABA   120.58 (-1.56%)
NIO   35.14 (-8.27%)
CGC   9.91 (-0.30%)
AMD   149.73 (+0.42%)
GE   94.99 (+2.14%)
MU   82.82 (-2.74%)
T   23.13 (+4.05%)
F   19.80 (+1.12%)
DIS   146.18 (+2.84%)
PFE   53.47 (-2.21%)
AMC   29.70 (+3.96%)
ACB   5.93 (-1.33%)
BA   198.15 (+5.29%)
S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.85 (-1.17%)
MSFT   329.98 (-0.03%)
FB   308.19 (-0.78%)
GOOGL   2,855.73 (+1.23%)
AMZN   3,434.48 (-0.27%)
TSLA   1,075.21 (-1.81%)
NVDA   321.28 (+2.20%)
BABA   120.58 (-1.56%)
NIO   35.14 (-8.27%)
CGC   9.91 (-0.30%)
AMD   149.73 (+0.42%)
GE   94.99 (+2.14%)
MU   82.82 (-2.74%)
T   23.13 (+4.05%)
F   19.80 (+1.12%)
DIS   146.18 (+2.84%)
PFE   53.47 (-2.21%)
AMC   29.70 (+3.96%)
ACB   5.93 (-1.33%)
BA   198.15 (+5.29%)
S&P 500   4,587.26 (+1.64%)
DOW   34,708.71 (+2.02%)
QQQ   388.77 (+0.43%)
AAPL   162.85 (-1.17%)
MSFT   329.98 (-0.03%)
FB   308.19 (-0.78%)
GOOGL   2,855.73 (+1.23%)
AMZN   3,434.48 (-0.27%)
TSLA   1,075.21 (-1.81%)
NVDA   321.28 (+2.20%)
BABA   120.58 (-1.56%)
NIO   35.14 (-8.27%)
CGC   9.91 (-0.30%)
AMD   149.73 (+0.42%)
GE   94.99 (+2.14%)
MU   82.82 (-2.74%)
T   23.13 (+4.05%)
F   19.80 (+1.12%)
DIS   146.18 (+2.84%)
PFE   53.47 (-2.21%)
AMC   29.70 (+3.96%)
ACB   5.93 (-1.33%)
BA   198.15 (+5.29%)
NASDAQ:CDMO

Avid Bioservices Stock Forecast, Price & News

$30.97
+0.42 (+1.37%)
(As of 12/2/2021 01:45 PM ET)
Add
Compare
Today's Range
$30.06
$32.02
50-Day Range
$20.50
$34.18
52-Week Range
$8.76
$34.51
Volume
15,568 shs
Average Volume
725,059 shs
Market Capitalization
$1.90 billion
P/E Ratio
387.17
Dividend Yield
N/A
Beta
2.29
30 days | 90 days | 365 days | Advanced Chart
Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.


Avid Bioservices logo

About Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
255
Year Founded
N/A

Sales & Book Value

Annual Sales
$95.87 million
Cash Flow
$0.25 per share
Book Value
$1.28 per share

Profitability

Net Income
$11.21 million
Pretax Margin
12.63%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,427,000
Market Cap
$1.90 billion
Optionable
Optionable

Company Calendar

Last Earnings
9/07/2021
Today
12/02/2021
Next Earnings (Confirmed)
12/07/2021
Fiscal Year End
4/30/2022

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

532nd out of 1,391 stocks

Pharmaceutical Preparations Industry

246th out of 669 stocks

Analyst Opinion: 1.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

Is Avid Bioservices a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices
or view top-rated stocks.

How has Avid Bioservices' stock been impacted by Coronavirus (COVID-19)?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDMO shares have increased by 586.7% and is now trading at $30.97.
View which stocks have been most impacted by COVID-19
.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Tuesday, December 7th 2021.
View our earnings forecast for Avid Bioservices
.

How can I listen to Avid Bioservices' earnings call?

Avid Bioservices will be holding an earnings conference call on Tuesday, December 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) released its quarterly earnings results on Tuesday, September, 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.06. The biopharmaceutical company earned $30.75 million during the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a net margin of 12.63% and a trailing twelve-month return on equity of 19.89%. During the same period in the previous year, the firm posted $0.06 EPS.
View Avid Bioservices' earnings history
.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2022 earnings guidance on Thursday, October, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $115 million-$117 million, compared to the consensus revenue estimate of $115.83 million.

What price target have analysts set for CDMO?

3 brokerages have issued twelve-month price targets for Avid Bioservices' stock. Their forecasts range from $27.00 to $29.00. On average, they expect Avid Bioservices' share price to reach $28.00 in the next twelve months. This suggests that the stock has a possible downside of 9.6%.
View analysts' price targets for Avid Bioservices
or view top-rated stocks among Wall Street analysts.

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.15%), AltraVue Capital LLC (4.02%), Invesco Ltd. (1.96%), Jennison Associates LLC (1.72%), Geode Capital Management LLC (1.63%) and Dimensional Fund Advisors LP (1.44%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices
.

Which major investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Pier Capital LLC, Cinctive Capital Management LP, Morgan Stanley, Renaissance Technologies LLC, Squarepoint Ops LLC, Kornitzer Capital Management Inc. KS, and Invesco Ltd.. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, Mark R Ziebell, Nicholas Stewart Green, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices
or view top insider-selling stocks.

Which major investors are buying Avid Bioservices stock?

CDMO stock was acquired by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Jennison Associates LLC, Millennium Management LLC, CastleArk Alternatives LLC, Phocas Financial Corp., Dimensional Fund Advisors LP, Peregrine Capital Management LLC, and Assenagon Asset Management S.A.. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices
or or view top insider-buying stocks.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $30.97.

How much money does Avid Bioservices make?

Avid Bioservices has a market capitalization of $1.90 billion and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 255 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

Where are Avid Bioservices' headquarters?

Avid Bioservices is headquartered at 2642 Michelle Drive Suite 200, TUSTIN CA, 92780.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at [email protected], or via fax at 714-838-5817.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contac[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.